Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA). Jeffrey D.

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

The symptoms of COPD aren’t always obvious. Subtle signs like finding it harder to keep up with friends on a walk or unconsciously cutting down on physical activity can be easy to miss. Some people ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung diseases that include emphysema and chronic bronchitis. 1 Those living with COPD can experience coughing, wheezing, ...

Triple therapy in COPD significantly improves lung function vs LAMA monotherapy, LABA/LAMA, and ICS/LABA, although evidence showing this is often low quality. Triple therapy is likely effective, safe, ...

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...

bronchodilators, COPD Triple therapy with budesonide/glycopyrrolate/formoterol fumarate in patients with COPD, regardless of exacerbation history, reduced ...

Add Yahoo as a preferred source to see more of our stories on Google. Woman’s World has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Sure, ...